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bBritish Columbia Cancer Agency, Vancouver, British Columbia, CanadaAbstractPurpose: The purpose of this study was to assess the influence of positron emission tomographyecomputed tomography (PET-CT) results on
patient management from a single Canadian oncology center during its first 2 years of operation.
Methods: A total of 3,779 consecutive patients, 18 years of age and older, who were referred for PET-CT imaging at the British Columbia
Cancer Agency between July 1, 2005 and June 30, 2007, were included in this analysis. Results were tabulated from a standard questionnaire,
which was given to referring physicians following completion of their patient’s PET-CT study.
Results: From July 1, 2005 to June 30, 2007, 3,779 consecutive fluoro-2-deoxyglucose PET-CT examinations were performed in patients
aged 18 years or older. A total of 3,429 referring-physician surveys (90.7%) were returned. The results of the PET-CT study resulted in
a change in treatment decision in 49.8% of the studies and resulted in improved decision making in 83.2% of the studies.
Conclusion: This series demonstrated that the results from PET-CT studies performed at a single Canadian oncology center during the
first 2 years of its operation altered patient management in 50% of cases and resulted in improved decision making in the majority of
cases.Abre´ge´Objet: L’objet de cette e´tude consistait a` e´valuer l’incidence des re´sultats de la tomographie par e´mission de positrons couple´e a` la tomo-
densitome´trie (TEP/TDM) sur la prise en charge des patients d’un centre d’oncologie canadien au cours de ses deux premie`res anne´es d’activite´.
Me´thodes: Au total, 3 779 patients conse´cutifs de 18 ans et plus qui avaient e´te´ dirige´s vers la British Columbia Cancer Agency pour une
imagerie TEP/TDM, du 1er juillet 2005 au 30 juin 2007, ont e´te´ inclus dans l’analyse. Les re´sultats ont e´te´ compile´s a` partir d’un ques-
tionnaire standard qui avait e´te´ remis a` tous les me´decins traitants apre`s l’examen TEP/TDM de leurs patients.
Re´sultats: Du 1er juillet 2005 au 30 juin 2007, 3 779 examens TEP/TDM au fluoroe2ede´soxyglucose conse´cutifs ont e´te´ re´alise´s chez des
patients de 18 ans et plus. Au total, 3 429 questionnaires (90,7 %) ont e´te´ retourne´s par les me´decins traitants. Les re´sultats de l’examen TEP/
TDM ont entraıˆne´ une modification du choix de traitement dans 49,8 % des cas et un meilleur choix de traitement dans 83,2 % des cas.
Conclusion: Cette se´rie a de´montre´ que les re´sultats des examens TEP/TDM re´alise´s dans un unique centre d’oncologie canadien au cours de
ses deux premie`res anne´es d’activite´ ont modifie´ la prise en charge des patients dans 50 % des cas et ont entraıˆne´ un meilleur choix de
traitement dans la majorite´ des cas.
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The Canadian Cancer Society and Statistics Canada esti-
mated that 171,000 new cancer cases (excluding 75,100ll rights reserved.
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will occur in Canada in 2009 [1].
Positron emission tomography (PET) is a nuclear medi-
cine imaging technology that allows noninvasive assessment
of physiological and biochemical processes within the body.
In oncology, PET provides information about the biochem-
ical or functional status of tissue, which is important,
because biochemical changes within tumours typically occur
before anatomic changes.
More recently, a combined PETecomputed tomography
(CT) scanner, with its shared mechanical components and
designs, provides an optimum platform to fuse anatomic
images from CT and functional or biochemical images from
PET. Details of PET-CT scanner instrumentation and a flow
chart of the typical PET-CT operation were reviewed by
Alessio et al [2]. A combined PET-CT scanner provides both
functional and anatomic information and has been incorpo-
rated into the diagnosis, staging, assessment of treatment
response, and assessment of residual disease in a variety of
cancer types.
To date the most widely used positron-emitting radio-
pharmaceutical in oncology has been fluoro-2-deoxyglucose
(FDG) labeled with fluorine-18. FDG is a glucose analog,
and the mechanism of cellular uptake and initial phosphor-
ylation is similar to that of glucose. However, once FDG is
phosphorylated to FDG-6-phosphate, it is not metabolized
further and becomes trapped within the cell and consequently
can be imaged by using PET. The degree of FDG accumu-
lation within the cell, as measured by PET, is proportional to
glucose uptake and metabolic activity of the tissue examined.
Cells that have undergone malignant transformation tend to
be hypermetabolic and demonstrate increased FDG transport
and metabolism because of accelerated cell proliferation and
increased hexokinase activity. Other positron-emitting
radiopharmaceuticals, such as labeled amino acids, DNA
precursors, tumour receptors, and cytostatic drugs, have also
been developed for potential application in oncologic PET
imaging [3e7]. Because many tumours contain heteroge-
neous cell populations, it is likely that multiple positron-
emitting radiopharmaceuticals may be necessary to
adequately evaluate the diversity of tumours confronted in
oncology.
The clinical use of PET scans is routine in the United
States, many European countries, Australia, and Japan. In the
United States, Medicare reimburses for PET scans for the
diagnosis, staging, and restaging of selected common cancers
[8]. In addition, reimbursement for most cancers can also be
obtained provided that data are submitted to a National
Oncologic PET Data Registry [9e11].
Although there are regional differences on the availability
of PET within Canada, as of November 2007, there were 22
centers that perform publicly funded oncologic PET scans in
7 Canadian provinces [12]. Because of shorter acquisition
times, the ability to provide a scaled attenuation correction
map, and improved anatomic localization, PET-CT has now
replaced dedicated PET for the systems currently being
manufactured and installed. The first PET-CT scanner wasinstalled in Canada in 2002. British Columbia has one
publicly funded PET-CT scanner, which began clinical
operations in July 2005. The purpose of this study was to
assess the influence of PET-CT results on patient manage-
ment from a single Canadian oncology center during the first
2 years of operation.
Patients and Methods
Consecutive patients, 18 years of age and older, who were
referred for FDG PET-CT imaging at the British Columbia
Cancer Agency (BCCA) between July 1, 2005 and June 30,
2007, were included in this analysis. Indications for perform-
ing PET-CT studies at the BCCA were approved by provincial
tumours groups and can be found at http://www.bccancer.bc.
ca/PPI/PET/indications.htm. Results were tabulated from
a standard questionnaire, which was given to all referring
physicians after the competition of their patient’s PET-CT
study. Referring physicians were asked to complete and return
the questionnaire within 1 week after completion of their
patient’s PET-CT study. Physicians who did not complete the
questionnaire were contacted by telephone 1e2 weeks after
the examination and provided a reminder. Studies were per-
formed under a clinical trial agreement with Health Canada,
and informed consent was obtained from all patients.
A total of 4,003 PET-CT studies were performed at the
BCCA from July 1, 2005 to June 30, 2007. Among these
studies, 3,779 scans were performed in patients 18 years of age
and older, and are included in this report. Patient preparation,
image acquisition, and processing parameters were performed
in accordance with the Society of Nuclear Medicine procedure
guidelines [13,14]. Precautions were taken to ensure that
female patients were not breast feeding or pregnant. Patients
were instructed to not consume any food or liquid (except
water) for 6 hours before the study. Patient were also instructed
to avoid chewing gum or strenuous exercise for 24 hours before
the study. Blood glucometer measurement was performed
before FDG administration.
With the patient resting comfortably, a weight-adjusted
amount of FDG, which ranged from 300 to 550 MBq, was
administered through a well-established intravenous line.
The uptake phase from injection to imaging was between 45
and 90 minutes. All patients were imaged in the 3-dimensioal
mode by using a CPS Biograph 16-slice Hi-Rez PET-CT
(Siemens, Hoffman Estate, IL). The majority of the patients
were scanned from the skull base to mid thigh with the arms
abducted. Patients with head and neck cancers underwent an
additional 2 bed position image of the head and neck, with
the arms adducted. Whole body imaging (top of head to feet)
was performed on selected patients with melanoma. For
whole body plus head and neck PET acquisitions, patients
were imaged for 3e4 minutes per bed position. For patients
being evaluated with primary central nervous system (CNS)
lesions, a dedicated single bed position 15-minute image of
the brain was obtained.
For the CT portion of the study image acquisition, volumetric,
noncontrast, 120 kVp, maximum 80 milliampere-second (mAs)
Figure 1. The number of positron emission tomographyecomputed tomog-
raphy studies performed in patients 18 years in year 1 and year 2.
Table 1
First 2 year’s referrals (N ¼ 3,779)
Referral type 2005e2006, N (%) 2006e2007, N (%)
Lung cancer
and/or SPNa
570 (37.8) 801 (35.4)
Lymphoma 251 (16.6) 255 (11.3)
Gastrointestinal cancer 234 (15.5) 471 (20.1)
Head and neck caner 149 (9.8) 230 (10.2)
Breast cancer 93 (6.1) 112 (4.9)
Melanoma 52 (3.4) 81 (3.6)
Gynecologic cancer 49 (3.2) 79 (3.5)
Testicular cancer 16 (1.1) 30 (1.3)
Sarcoma 14 (1.0) 33 (1.5)
Brain cancer 12 (0.8) 12 (0.5)
Thyroid cancer 18 (1.2) 25 (1.1)
Other 56 (3.7) 136 (6.0)
aIncludes known or suspected lung cancers and solitary pulmonary
nodules (SPN).
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acquired from the base of the brain to the mid thigh during tidal
expiration. Maximum tube current was increased to 100 mAs
for head and neck acquisitions. The table feed was 18 mm/
rotation, and slice thickness was 3 mm. PET data were
acquired after the CT study, and both PET and CT data, stan-
dard CT, and iterative PET reconstructions were applied.
Attenuation corrected PET emission, noncorrected PET
emission, and low mAs; noncontrast CT images were avail-
able for review by 3 experienced nuclear medicine physi-
cians. Clinical reports were typically issued within 1e2 days
after the completion of the study. Within 2 weeks of
receiving the clinical report, the referring physicians were
asked to complete a post-test questionnaire, which addressed
the indication for performing the PET study and the impact
of the study on the clinical care of the patients.
Results
Between July 1, 2005 and June 30, 2007, 3,779 PET-CT
consecutive examinations were performed in patients aged
18 years or older. A total of 1,986 men (mean age 61.3 years,
standard deviation [SD] 14.0 years) and 1,793 women (mean
age 60.0 years, SD 14.7 years) were studied. Among these
patients, 3,187 (84.3%) had a single study performed, 251
(6.6%) had 2 PET-CT studies performed, and 26 (0.7%) had
3 or more PET-CT studies.
During the first year of operation (July 2005 to June 2006),
1,514 studies were performed, and 2,265 studies were per-
formed in the second year (July 2006 to June 2007) (Figure 1).
Patients with solitary pulmonary nodules and proven or sus-
pected lung cancers were the most common type of referral and
accounted for 1,371 of the studies performed in the first 2 years
(36.3%). Other referral indications are tabulated in Table 1.
British Columbia is geographically divided into 5
different health authorities (Figure 2) [15]. The BCCA is
a population-based cancer-control organization that provided
cancer-related care for patients throughout the province. The
relative distribution of the adult population within the health
authorities and the percentage of patients referred from PET-
CT study within each region were similar, which reflected
a uniform usage of a provincial resource (Table 2).
A total of 3,429 referring physician surveys were returned
(90.7%). The referring physicians’ stated reasons for
ordering the PET-CT are included in Figure 3. The most
frequent reason for ordering a PET-CT study was tumour
staging, followed by evaluation of recurrent disease. The
value of the PET-CT study and the influence of the results on
the referring physician’s patient management are presented
in Table 3. The results of the PET-CT study resulted in
a change in treatment decision in 49.8% of the studies and
improved decision making in 83.2% of the studies.
Discussion
PET-CT is a noninvasive imaging technique that measures
the distribution and concentration of radiopharmaceuticalswithin the body. PET-CT scanners have become more widely
available within Canada. In the 5 years between 2002 and
2007, the number of PET-CT scanners in Canada increased to
18 scanners [16]. Although improvements have been made,
the number of PET scanners in Canada is fewer then other
countries. For example, it has been estimated that, in the
United States, there are approximately 5 PET scanners per
million people [17,18]. In a recent European study, it was
estimated that the prevalence of PET scanners within a devel-
oped country should be approximately 1 per million [19].
As shown in Table 2, the location of patient referrals for
PET-CT studies in both the first and the second year of
operation closely paralleled the population within the health
authority regions. This equitable assess to PET-CT within the
province is not surprising given that the BCCA is a pop-
ulation-based cancer-control organization that serves the
entire province.
FDG PET imaging in the oncologic patient was shown to
be useful and cost effective in many tumour types [20e26].
In the first 2 years of operation at the BCCA, the most
Figure 2. The current geographic distribution of British Columbia’s Health Authorities.
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staging, evaluation of recurrent disease, diagnosis, and
monitoring response to treatment; PET studies were used
most often in patients with lung cancer, gastrointestinal
cancer (primarily colon and esophageal carcinoma),
lymphoma, and head and neck cancers.
In the absence of prospective randomized outcome data;
evidence that a diagnostic test alters patient management and
results in improved decision making are important markers
of the intrinsic value of a test. This current study confirms
that the information derived from a PET-CT scan resulted in
a change in an individual patient’s treatment plan in 50% of
the cases and resulted in improved decision-making ability in
83% of cases. Theses results are similar to results from theTable 2
Locations of patient referrals for the first 2 yearsa
Geographic health region
(% of population >18 years)b 2005e2006, N (%) 2006e2007, N (%)
Fraser (34.1) 553 (36.5) 881 (38.9)
Vancouver Coastal (26.3) 447 (29.5) 611 (27.0)
Vancouver Island (17.4) 249 (16.4) 393 (17.4)
Interior (16.4) 186 (12.3) 268 (11.8)
Northern (6.2) 60 (4.0) 99 (4.4)
Out of province 19 (1.3) 13 (0.6)
aFrom http://www.bcstats.gov.bc.ca/DATA/POP/pop/dynamic/Population
Statistics.
bEstimated percentage of provincial population 18 years of age and older
in 2007.National Oncologic PET, which was initiated in May 2006
with the goal to collect data for cancers not currently covered
by the Center for Medicare and Medicaid services. The
National Oncologic PET Registry study evaluated nearly
23,000 patients and found that PET results were associated
with a change in patient management in 36.5% of cases [10].
In a smaller consecutive series from a smaller community-
based study, Tucker et al [27] demonstrated that PET scan-
ning changed patient management in 45% of studies and
resulted in improved decision-making ability in 89% of
studies.
Although the results of this study confirm that PET-CT
was important in the management and evaluation ofFigure 3. Reasons for ordering the test, July 2005 to June 2007 (N ¼ 3,429).
Table 3
The effect of positron emission tomographyecomputed tomography
(PET-CT) on patient management for the first 2 years (N ¼ 3429)
Question Yes, N (%) No, N (%)
Not answered,
N (%)
Did the PET-CT results change
the treatment plan
1,709 (49.8) 1,609 (46.9) 111 (3.2)
Did the PET-CT results improve
the decision-making ability
2,852 (83.2) 475 (13.9) 102 (3.0)
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Although this is a consecutive series, this study is a retro-
spective review of a registry and, therefore, is subject to
patient selection bias based on clinical need. For example,
a subset of patients being evaluated presented as diagnostic
dilemmas, and, therefore, it should not be too surprising that,
in a proportion of these cases, the results of additional tests
led to improved decision making. This patient selection bias
would be less for patient referred for staging of disease,
which was the most common reason for referral.
Physicians were not required to complete a pretest ques-
tionnaire, which would have provided information on the
referring physicians’ management plans if PETs were not
available. It is possible that the referring physicians may
have had an a priori bias that the PET-CT results would
change patient management, which may result in an over-
estimation of the magnitude of the benefit of the PET-CT
study. Another limitation was that, although many cases were
discussed and reviewed at tumour conferences, this study
made no attempt to systematically obtain histopathologic
follow-up to confirm PET scan results.
A final limitation of this study was that we failed to
incorporate whether the physician’s intention to change
patient management was actually carried out and whether the
resultant change in patient management had a positive
impact on patient outcome. The inference that a resultant
change in patient management is a positive benefit may be
false. A PET-CT scan result, which appropriately does not
alter patient management, would be more beneficial than
results that inappropriately changed patient management.
However, if there were a significant number of cases in
which the PET-CT scan results inappropriately altered
patient management, then one would not expect that 83% of
studies would lead to improved decision making.
In conclusion, evidence that demonstrates that a diag-
nostic test alters patient management and results in improved
decision making for the patient is the foundation of any
newly introduced test. In this population-based series, we
confirmed that the results from FDG PET-CT studies both
altered patient management in 50% of cases and improved
decision making in 83% of cases. The information provided
to clinicians should result in better stage-specific and patient-
specific therapies, which should translate into better patient
outcomes. Further research is required to link the changes in
patient management and improvement in decision making,
with improved outcome and cost-effectiveness.References
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